(Date:11/24/2009)... , SAN MATEO, Calif., Nov. 24 /PRNewswire-...biopharmaceutical company focused on developing an... announced today that Anthony DiTonno, President a...t at the 21st Annual Piper Jaffray Health Care Con...York Palace Hotel in New York, New York. ,, Mr...
(Date:11/24/2009)... The FBI recently approved the...ories participating in or generating DNA records f... Madison, WI USA (PRWEB) -- The FBI rece...stem for use by laboratories participating in, or...x System (NDIS). NDIS currently contains more than...
(Date:11/24/2009)... , DUBLIN, November 24 /PRNewswire-FirstC... global specialty biopharmaceutical company, today...pean Medicines Agency for,velaglucerase alfa, the ...t,for the treatment of Type 1 Gaucher disease. Thi...rase alfa that has been submitted, with previous,s...
(Date:11/24/2009)... , BOZEN, Italy, November 24 /PRNewswir...formed a new Canadian joint venture with a group o...-based company will operate under the,name Health ...d support,Health Robotics, i.v. Room of the Future... offerings i.v.STATION(TM), i.v.SOFT(TM), and OMM(...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3...el, March 4 D-Pharm announced today that,it has h... with the FDA to,discuss the forthcoming IND submi...lowing acute stroke. The Pre-IND meeting focused o...ogram and the discussion,included clinical trials ...,and the FDA requirements and suggestions for the ...
...ch 4 /PRNewswire/ - Enerkem today announced progre...tion plant for the production,of cellulosic ethano... one of the first plants,in the world to make cell...duce 1.5 million gallons of cellulosic ethanol fro...les). This first demonstration plant represents,a ...
...entists Will Present at First Joint U.S. National ...March 11-12, 2008, MOUNTAIN VIEW, Calif., Mar. 4 ... provider of software, strategic,consulting, and r...velopment, today announced its broad-based partici...nference on Pharmacometrics (ACoP). Pharsight,scie...
Other Biology Technology:D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99 2Enerkem announces progress on construction of Canada's first cellulosic ethanol plant 2Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics 2Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics 3Chicken Anti-Human AP2M1 Antibody, Unconjugated from ABR-Affinity BioReagents
Mouse Anti-Dynamin Monoclonal Antibody, Unconjugated, Clone D5 from MBL International
Rabbit Anti-Human CSRP2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Mouse Anti-Mouse BKBeta2 potassium channel Monoclonal Antibody, Unconjugated, Clone N53/32 from UC Davis/NINDS/NIMH NeuroMab Facility
Biology Products: